Related Experiment Video

Updated: Jun 7, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition

Carmen Blanco-Aparicio1, Ana María García Collazo, Julen Oyarzabal

  • 1Spanish National Cancer Research Centre, Madrid, Spain.

Cancer Letters
|November 6, 2010
PubMed

Insights

The serine/threonine Pim 1 kinase is an oncogene implicated in cancer. A novel inhibitor, ETP-45299, shows promise, especially when combined with a PI3K inhibitor, suggesting a new therapeutic strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The serine/threonine Pim 1 kinase is an oncogene frequently deregulated in human cancers.
  • Pim 1 overexpression promotes cell cycle progression and inhibits apoptosis, making it a therapeutic target.
  • Developing selective Pim 1 inhibitors is crucial for cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy of ETP-45299, a potent and selective Pim 1 inhibitor.
  • To investigate the synergistic effects of combining ETP-45299 with a PI3K inhibitor (GDC-0941).

Main Methods:

  • ETP-45299's ability to inhibit phosphorylation of Bad and 4EBP1 was assessed in cellular models.
  • The anti-proliferative effects of ETP-45299 on various human tumor cell lines were evaluated.
  • Synergistic effects of ETP-45299 combined with GDC-0941 were studied in MV-4-11 AML cells.

Main Results:

  • ETP-45299 effectively inhibited Pim 1 targets (Bad, 4EBP1) and suppressed proliferation in multiple human tumor cell lines.
  • A strong synergistic effect was observed when ETP-45299 was combined with the PI3K inhibitor GDC-0941 in MV-4-11 AML cells.

Conclusions:

  • ETP-45299 demonstrates potent anti-cancer activity by inhibiting Pim 1 kinase.
  • The combination of selective Pim kinase inhibitors and PI3K inhibitors may offer significant clinical benefits for cancer patients.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...